加载中
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
常规交易时段
US$1.715
−US$0.015 · -0.87%
盘中时间采用ET。市场数据可能有所延迟。
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
日内区间
当前US$1.715
52周区间
当前US$1.715
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
40
偏贵
情绪
56
多空交织
风险
60
风险偏高
动量
19
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
日内区间
当前US$1.715
52周区间
当前US$1.715
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 9448万 USD | 3831.5万 USD | 1645.8万 USD | 1546.7万 USD | 1246.2万 USD |
| 销售、一般及管理费用 | 2868.5万 USD | 2398.2万 USD | 847万 USD | 326万 USD | 315.5万 USD |
| 营业费用 | 1.23亿 USD | 6229.7万 USD | 2606万 USD | 1942.7万 USD | 1587万 USD |
| 利息收入 | 942.6万 USD | 1041.3万 USD | 111.7万 USD | 12.9万 USD | 2.5万 USD |
| 利息支出 | 299.4万 USD | 279.8万 USD | 495.3万 USD | 142.3万 USD | 502.4万 USD |
| 折旧和摊销 | 50.9万 USD | 32.3万 USD | 17.5万 USD | 23.8万 USD | 27.2万 USD |
| 营业利润 | −1.23亿 USD | −6229.7万 USD | −2606万 USD | −1942.7万 USD | −1587万 USD |
| 净利润 | −1.17亿 USD | −5514.2万 USD | −9991.7万 USD | −2446.2万 USD | −2344.1万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
